An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple
Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)
This trial is designed to estimate the efficacy of a carfilzomib-based triplet in first or
second relapse of multiple myeloma for subjects refractory to lenalidomide. The study is an
open-label, phase 2 trial. Approximately 85 subjects will be enrolled in the study. Subjects
may receive treatment until progression.
Myeloma disease status will be monitored locally for response and progression per
International Myeloma Working Group (IMWG) criteria (Kumar et al, 2016) every 28 ± 7 days
from cycle 1 day 1 until confirmed progressive disease (PD), death, lost to follow-up, or
withdrawal of full consent (whichever occurs first), regardless of cycle duration, dose
delays or treatment discontinuation. Subjects with a suspected complete response (CR) or
better will have a bone marrow for minimal residual disease (MRD) assessment at 12 and 24
months (± 4 weeks) from start of treatment (unless a MRD assessment was performed within 4
months before planned assessment).
Subjects who end study drug(s) without confirmed PD are required to complete disease response
assessments and report new anti-myeloma treatment every 28 ± 7 days until first subsequent
anti-myeloma treatment, death, lost to follow-up, withdrawal of full consent, confirmed PD,
or end of study, whichever occurs first. Subjects who discontinue treatment and either start
new antimyeloma treatment or have PD will enter long-term follow-up every 12 weeks until
death or end of study.
Approximately 85 subjects will be enrolled in the study, with approximately one-third of
subjects in first relapse and two-thirds in second relapse.
This study will enroll adults ≥ 18 years of age with first or second relapse multiple
myeloma.
Eligible subjects will have relapsed multiple myeloma after receiving 1 or 2 prior lines of
therapy.
Subjects must be refractory to lenalidomide. Subjects may not have received prior
pomalidomide. Prior exposure to a proteasome inhibitor is allowed. Subjects previously
exposed to carfilzomib must have responded with at least a partial response to carfilzomib,
must not have discontinued carfilzomib due to toxicity, may not have relapsed while receiving
or within 60 days of the last dose of carfilzomib, and must have at least a 6 month
carfilzomib treatment-free interval since their last dose of carfilzomib.
Subjects must have measurable disease per IMWG consensus criteria, Eastern Cooperative
Oncology Group Performance Status (ECOG PS) of 0 to 2, and at least partial response (PR) to
1 line of therapy.
Inclusion Criteria
- Subject has provided informed consent prior to initiation of any study specific
activities or procedures.
- Male or female subjects age ≥ 18 years
- First or second relapse of multiple myeloma by International Myeloma Working Group
(IMWG) criteria (subjects refractory to the most recent line of therapy, excluding
carfilzomib, are eligible)
- Refractory to lenalidamide
- Measurable disease with at least 1 of the following assessed within 28 days prior to
enrollment:
- IgG multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
- IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL
- urine M-protein ≥ 200 mg per 24 hours
- in subjects without measurable serum or urine M-protein, serum-free light chain
(SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
- Must have at least a partial response (PR) to at least 1 line of prior therapy
- Prior therapy with PI is allowed. Subjects receiving prior carfilzomib therapy must
have achieved at least a PR, was not removed due to toxicity, did not relapse within
60 days from discontinuation of carfilzomib, and must have at least a 6 month
carfilzomib treatment-free interval from their last dose of carfilzomib
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2
Exclusion Criteria
- Primary refractory multiple myeloma
- Waldenström macroglobulinemia
- Multiple myeloma of IgM subtype
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes)
- Plasma cell leukemia ( greater than 2.0 × 109/L circulating plasma cells by
differential). If automated differential shows ≥ 20% of other cells, obtain manual
differential to identify other cells.
- Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of
amyloid plaques found on biopsy would be eligible if all other criteria are met)
- Previous diagnosis of amyloidosis associated with myeloma
- Myelodysplastic syndrome
- Toxicity requiring discontinuation of lenalidomide therapy
- Prior treatment with pomalidomide